MLICM
CRNX icon

Metropolitan Life Insurance Company (MetLife)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,573
Closed -$167K – 510
2024
Q1 		$167K Sell
3,573
-182
-5% -$7.12K 0.01% 790
2023
Q4 		$134K Hold
3,755
– – 0.01% 934
2023
Q3 		$112K Buy
3,755
+906
+32% +$18.7K 0.01% 953
2023
Q2 		$51.3K Hold
2,849
– – ﹤0.01% 1398
2023
Q1 		$45.8K Sell
2,849
-342
-11% -$6.33K ﹤0.01% 1433
2022
Q4 		$58.4K Hold
3,191
– – ﹤0.01% 1372
2022
Q3 		$62.7K Hold
3,191
– – ﹤0.01% 1302
2022
Q2 		$59.5K Buy
3,191
+429
+16% +$8.56K ﹤0.01% 1388
2022
Q1 		$60.6K Sell
2,762
-9,063
-77% -$183K ﹤0.01% 1480
2021
Q4 		$336K Buy
11,825
+2,165
+22% +$53.4K ﹤0.01% 1674
2021
Q3 		$203K Hold
9,660
– – ﹤0.01% 2056
2021
Q2 		$182K Buy
9,660
+1,974
+26% +$34.7K ﹤0.01% 2216
2021
Q1 		$117K Sell
7,686
-1,106
-13% -$17.1K ﹤0.01% 2354
2020
Q4 		$124K Hold
8,792
– – ﹤0.01% 2243
2020
Q3 		$138K Hold
8,792
– – ﹤0.01% 2026
2020
Q2 		$154K Buy
8,792
+4,619
+111% +$78.7K ﹤0.01% 1988
2020
Q1 		$61.3K Hold
4,173
– – ﹤0.01% 2317
2019
Q4 		$105K Buy
+4,173
New +$79.4K ﹤0.01% 2306
2019
Q3 		– Sell
-925
Closed -$23.1K – 2581
2019
Q2 		$23.1K Buy
+925
New +$22.9K ﹤0.01% 2590

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CRNX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2024, closing a stake of 3,573 shares — an estimated $167K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CRNX in Q2 2019 and held it in 19 quarters. The position peaked at $336K in Q4 2021. 234 funds tracked by Wall St. Rank hold CRNX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Crinetics Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,573 Crinetics Pharmaceuticals shares in Q2 2024, an estimated $167K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Crinetics Pharmaceuticals in Q2 2019 and held it in 19 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Crinetics Pharmaceuticals position peaked at $336K in Q4 2021.
  • 234 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.